Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease

Journal of Clinical Pharmacology

Volumn 55, Issue 2, 2015, Pages 221-229

  Hu, Chuanpu ^a   Adedokun, Omoniyi ^a   Ito, Kaori ^b   Raje, Sangeeta ^b   Lu, Ming ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b PFIZER INC   (United States)

Author keywords

bapineusumab; confirmatory approach; nonlinear mixed effect modeling; population pharmacokinetics; Type I error

Indexed keywords

BAPINEUZUMAB; MONOCLONAL ANTIBODY; NOOTROPIC AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD LEVEL; BODY WEIGHT; BOOTSTRAPPING; CAUCASIAN; COMPARTMENT MODEL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; ELIMINATION HALF-LIFE; HUMAN; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VOLUME OF DISTRIBUTION; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; FEMALE; GENETICS; HALF LIFE TIME; MALE; METABOLISM; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIBODIES, MONOCLONAL, HUMANIZED; BODY WEIGHT; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NOOTROPIC AGENTS;

EID: 84920935607     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.393     Document Type: Article

References (26)

1. Hardy J, Selkoe DJ,. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297: 353-356.
2. Ribbing J, Jonsson EN,. Power, selection bias and predictive performance of the population pharmacokinetic covariate model. J Pharm Pharmacodyn. 2004; 31: 109-134.
3. Harrell F,. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer Verlag; 2001.
4. Gastonguay MR,. A full model estimation approach for covariate effects: inference based on clinical importance and estimation precision. AAPS J. 2004; 6: S1.
5. Hu C, Dong Y,. Estimating the predictive quality of dose-response after model selection. Stat Med. 2007; 26: 3114-3139.
6. Shen X, Huang H, Ye J,. Inference after model selection. J Am Stat Assoc. 2004; 99: 751-762.
7. Hu C, Zhou H,. An improved approach for confirmatory phase III population pharmacokinetic analysis. J Clin Pharmacol. 2008; 48: 812-822.
8. Hu C, Zhang J, Zhou H,. Confirmatory analysis for phase III population pharmacokinetics. Pharm Stat. 2011; 10: 14-26.
9. Hu C, Zhou H,. Statistical issues in dug-drug interaction assessment for therapeutic biologics. In, Zhou H, Meibohm B, eds. Drug-Drug Interaction for Therapeutic Biologics. Hoboken, NJ: John Wiley & Sons; 2013.
10. Chow AT, Earp JC, Gupta M, et al. Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions. J Clin Pharmcol. 2014; 54: 593-601.
11. Sheiner LB,. Learning versus confirming in clinical drug development. Clin Pharmacol Ther. 1997; 61: 275-291.
12. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014; 370: 322-333.
13. Hu C, Szapary PO, Mendelsohn AM, Zhou H,. Latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint. J Pharmacokinet Pharmacodyn. 2014.
14. Cohen J,. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. New Jersey: Erlbaum; 1988.
15. Xu Z, Vu T, Lee H, et al. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol. 2009; 49: 1056-1070.
16. Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009; 49: 162-175.
17. West GB, Brown JH, Enquist BJ,. A general model for the origin of allometric scaling laws in biology. Science. 1997; 276: 122-126.
18. Savic RM, Karlsson MO,. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009; 11: 558-569.
19. Holford NHG,. The Visual Predictive Check-Superiority to Standard Diagnostic (Rorschach) Plots. http://www.page-meeting.org/default.asp?abstract=738. 2005.
20. Efron B, Tibshirani RJ,. An Introduction to the Bootstrap. New York: CRC Press; 1994.
21. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO,. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011; 13: 143-151.
22. Beal SL, Sheiner LB, Boeckmann A, Bauer RJ,. NONMEM User's Guides (1989-2009). Ellicott City, MD, USA: Icon Development Solutions; 2009.
23. Gibiansky L, Gibiansky E,. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. Expert Opin Drug Metab Toxicol. 2009; 5: 803-812.
24. Xu Z, Vu T, Lee H, et al. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-a human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharm. 2010; 49: 1056-1070.
25. Hu C, Wasfi Y, Zhuang Y, Zhou H,. Information contributed by meta-analysis in exposure-response modeling: application to phase 2 dose selection of a related therapeutic proteinguselkumab in patients with moderate-to-severe psoriasis. J Pharm Pharmacodyn. 2014; 41 (3): 239-250.
26. Davda JP, Hansen RJ,. Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets. MAbs. 2010; 2: 576-588.